EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MediPharm Labs Corp (MEDIF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of MediPharm Labs Corp $0.04, price $0.05, upside -23.6%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Canada · ISIN CA58504D1006

ML MediPharm Labs Corp logo Thin data Sep 24, 2026

MediPharm Labs Corp

MEDIF · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.0404 · Overvalued (−23.6%)
!Quality 44/100
!Mixed Growth (revenue 5y +4.6 %/yr)
!Loss-making · -20.2% net margin (TTM)
!Low debt · negative free cash flow
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch MediPharm Labs Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.3750 $0.0413 Fair Value $0.0404 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0413 – $0.3750 · fair‑value band $0.0353 – $0.0456 · the $0.0529 price screens above the $0.0404 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally.

Show more

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.

Stock analysis

MediPharm Labs Corp (MEDIF) currently trades at $0.0529, while our model-based Fair Value estimate is $0.0404, 23.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0353 (bear) to $0.0456 (bull), the price of $0.0529 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

MediPharm Labs Corp reported revenue of C$45.1M in FY2025 versus C$21.7M in FY2021, a compound +20.1%/yr. Reported net income was −C$8.3M in FY2025.

Key figures

Market cap $22.3M · P/S ratio 0.51 · EPS (TTM) $−0.0100 · Net margin −18.3% · Return on equity −22.3% · Return on assets (EBIT) −31.4% · Operating margin −11.1% · Revenue (TTM) $43.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 21% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −24%, MEDIF screens richer than that median.

Fair Value models

Bear $0.0353 Fair Value $0.0404 Bull $0.0456
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0300 $0.0400 $0.0600 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0600 54

Open the full fair value analysis →

Notify me when MEDIF reaches fair value

Put MEDIF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 44 · Market factors (momentum, volatility) 38

Profitability 26
Margins and returns on capital today
Quality Growth 73
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 35
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 35
Distance to the 52-week high (market factor)
Net Issuance 28
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−197.2% (2020) → −18.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MEDIF screens overvalued: fair value 24% below the price. Compare with Merck KGaA →

Compare MediPharm Labs Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −33.3% · Below median
Profitability
Return on assets −10.2% · Bottom 25%
Net margin (TTM) −20.2% · Bottom 25%
Operating margin (TTM) −11.1% · Bottom 25%
Growth and dividend
Revenue growth −17.1% · Bottom 25%
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.62× · Cheapest 25%
P/S (TTM) 0.51× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MediPharm Labs Corp · Fair Value
$0.0404 −24%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "MediPharm Labs Corp Fair Value". https://www.fairvalue-calculator.com/stock/MEDIF

Frequently asked questions

Is MediPharm Labs Corp (MEDIF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0404 versus a price of $0.0529, about −24% upside (overvalued).
What is the fair value of MEDIF?
Our model-based fair value for MediPharm Labs Corp is $0.0404 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0529.
What is the quality score of MEDIF?
MediPharm Labs Corp has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MediPharm Labs Corp (MEDIF)?
Our model-based price target is the fair value of $0.0404 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.0353, optimistic scenario $0.0456. It is a calculation from audited fundamentals, not an analyst target.
What is the MediPharm Labs Corp stock forecast for 2026?
Our models put fair value at $0.0404, about −24% upside versus a price of $0.0529 (overvalued). Cautious scenario $0.0353, optimistic scenario $0.0456. The calculation is refreshed regularly with new filings.
What is the revenue of MediPharm Labs Corp (MEDIF)?
MediPharm Labs Corp reported trailing-twelve-month revenue of about $43.3M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of MediPharm Labs Corp (MEDIF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MediPharm Labs Corp it is $0.0404 per share (as of Sep 24, 2026), against a price of $0.0529. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MediPharm Labs Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MEDIF trades above its calculated fair value: price $0.0529, fair value $0.0404, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDIF?
No. The price is what the market pays today ($0.0529); the fair value is what the company's own numbers justify ($0.0404). For MediPharm Labs Corp the two are $0.0125 per share apart. That gap is exactly why we show both numbers side by side.
How much is MediPharm Labs Corp worth?
The market values MediPharm Labs Corp at about $22.3M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0529; our models calculate a fair value of $0.0404 per share.
What do the bullish and bearish scenarios say about MEDIF?
Our models span a range for MediPharm Labs Corp: cautious scenario $0.0353, base $0.0404, optimistic $0.0456 per share (as of Sep 24, 2026, price $0.0529). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MediPharm Labs Corp (MEDIF)?
Balance-sheet figures for MediPharm Labs Corp (as of Sep 24, 2026): return on equity −22.3%, debt of 0.29 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is MEDIF from its 52-week high?
MediPharm Labs Corp trades at $0.0529, about 21% below its 52-week high of $0.0670 and 26% above the low of $0.0420 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0404 is for.
Which stocks are comparable to MediPharm Labs Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MediPharm Labs Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0529, calculated fair value $0.0404 (−24%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDIF calculated?
We run MediPharm Labs Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0404, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. MediPharm Labs Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MediPharm Labs Corp (MEDIF)?
The closing price on Oct 2, 2026 was $0.0529. Our model-based fair value is $0.0404, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MediPharm Labs Corp right now?
The price sits above even our optimistic bull case ($0.0456). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of MediPharm Labs Corp

How large is the market capitalisation of MediPharm Labs Corp (MEDIF)?
The market capitalisation of MediPharm Labs Corp is $22.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MediPharm Labs Corp (MEDIF)?
The price-to-sales ratio of MediPharm Labs Corp is 0.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MediPharm Labs Corp (MEDIF)?
Earnings per share at MediPharm Labs Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MediPharm Labs Corp (MEDIF)?
The net margin of MediPharm Labs Corp is −18.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MediPharm Labs Corp (MEDIF)?
The return on equity (ROE) of MediPharm Labs Corp is −22.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MediPharm Labs Corp (MEDIF)?
On an EBIT basis the return on assets of MediPharm Labs Corp is −31.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MediPharm Labs Corp (MEDIF)?
The operating margin of MediPharm Labs Corp is −11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MediPharm Labs Corp (MEDIF)?
Revenue at MediPharm Labs Corp is growing −17.1% versus a year earlier (3y avg +26.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MediPharm Labs Corp (MEDIF) generate?
The free cash flow of MediPharm Labs Corp is −$5.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch MediPharm Labs Corp in the live analysis

One click puts MediPharm Labs Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.